(AURA) Aura Biosciences - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 757m USD | Total Return: 28% in 12m
Avg Turnover: 3.71M
Warnings
Share dilution 34.6% YoY
Altman Z'' -15.00 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
No distinct edge detected
Aura Biosciences Inc (AURA) is a Boston-based, clinical-stage biotechnology firm specializing in precision oncology. The company utilizes a proprietary platform to develop virus-like drug conjugates (VDCs), which leverage virus-like particles to deliver therapeutic agents directly to solid tumor cells while sparing healthy tissue.
The company’s lead candidate, bel-sar, is currently in late-stage clinical trials for primary choroidal melanoma and is undergoing early-stage evaluation for bladder cancer applications. In the biotechnology sector, clinical-stage companies often face high research and development costs and regulatory hurdles before achieving commercialization. This VDC business model aims to improve the safety profile of traditional chemotherapy by utilizing targeted delivery mechanisms.
Investors may find it useful to review the detailed financial metrics and pipeline updates available on ValueRay. Aura Biosciences has been a publicly traded entity since its October 2021 IPO and operates within the small-cap segment of the healthcare sector.
- Bel-sar Phase 3 CoMpass trial results for choroidal melanoma
- Clinical data readouts for bel-sar in non-muscle invasive bladder cancer
- FDA regulatory pathway and potential accelerated approval for ocular oncology
- Cash runway and capital allocation for late-stage clinical development
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.67 > 0.02 and ΔFCF/TA -15.04 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.66 > 3% & CFO -91.3m > Net Income -112.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 7.09 > 1.5 & < 3 |
| Outstanding Shares: last quarter (67.4m) vs 12m ago 34.56% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.80%; Δ -0.80% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.74 (Total Current Assets 118.5m - Total Current Liabilities 16.7m) / Total Assets 137.7m |
| B: -3.73 (Retained Earnings -514.1m / Total Assets 137.7m) |
| C: -0.80 (EBIT TTM -117.0m / Avg Total Assets 146.5m) |
| D: -16.90 (Book Value of Equity -514.3m / Total Liabilities 30.4m) |
| Altman-Z'' = -30.43 = D |
As of May 24, 2026, the stock is trading at USD 7.60 with a total of 278,175 shares traded.
Over the past week, the price has changed by -1.81%,
over one month by +1.47%,
over three months by +38.69% and
over the past year by +27.95%.
Aura Biosciences has received a consensus analysts rating of 4.57. Therefore, it is recommended to buy AURA.
- StrongBuy: 4
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 18.8 | 147.4% |
Revenue TTM = 0.0 USD
EBIT TTM = -117.0m USD
EBITDA TTM = -115.9m USD
Long Term Debt = 13.7m USD (estimated: total debt 17.0m - short term 3.27m)
Short Term Debt = 3.27m USD (from shortTermDebt, last quarter)
Debt = 17.0m USD (from shortLongTermDebtTotal, last quarter) (leases 17.4m already included)
Net Debt = -97.7m USD (calculated: Debt 17.0m - CCE 114.7m)
Enterprise Value = 659.0m USD (756.8m + Debt 17.0m - CCE 114.7m)
Interest Coverage Ratio = unknown (Ebit TTM -117.0m / Interest Expense TTM 0.0)
EV/FCF = -7.19x (Enterprise Value 659.0m / FCF TTM -91.6m)
FCF Yield = -13.91% (FCF TTM -91.6m / Enterprise Value 659.0m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 274k) / Revenue TTM)
Tobins Q-Ratio = 4.79 (Enterprise Value 659.0m / Total Assets 137.7m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 17.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = -92.4m (EBIT -117.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.09 (Total Current Assets 118.5m / Total Current Liabilities 16.7m)
Debt / Equity = 0.16 (Debt 17.0m / totalStockholderEquity, last quarter 107.2m)
Debt / EBITDA = 0.84 (negative EBITDA) (Net Debt -97.7m / EBITDA -115.9m)
Debt / FCF = 1.07 (negative FCF - burning cash) (Net Debt -97.7m / FCF TTM -91.6m)
Total Stockholder Equity = 143.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -76.70% (Net Income -112.4m / Total Assets 137.7m)
RoE = -17.08% (Net Income TTM -112.4m / Total Stockholder Equity 658.0m)
RoCE = -17.42% (EBIT -117.0m / Capital Employed (Equity 658.0m + L.T.Debt 13.7m))
RoIC = -74.50% (negative operating profit) (NOPAT -92.4m / Invested Capital 124.0m)
WACC = 9.23% (E(756.8m)/V(773.8m) * Re(9.44%) + D(17.0m)/V(773.8m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.44% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.11 | Cagr: 20.38%
[DCF] Fair Price = unknown (Cash Flow -91.6m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.32 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.38 | Chg30d=+7.41% | Revisions=+14% | Analysts=0
EPS next Quarter (2026-09-30): EPS=-0.37 | Chg30d=+6.37% | Revisions=+14% | Analysts=0
EPS current Year (2026-12-31): EPS=-1.59 | Chg30d=+0.47% | Revisions=+14% | GrowthEPS=+9.4% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-1.67 | Chg30d=-2.30% | Revisions=-14% | GrowthEPS=-4.5% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +14%